KR102317622B1 - Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도 - Google Patents

Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도 Download PDF

Info

Publication number
KR102317622B1
KR102317622B1 KR1020197000200A KR20197000200A KR102317622B1 KR 102317622 B1 KR102317622 B1 KR 102317622B1 KR 1020197000200 A KR1020197000200 A KR 1020197000200A KR 20197000200 A KR20197000200 A KR 20197000200A KR 102317622 B1 KR102317622 B1 KR 102317622B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
expression
cas9
cells
aare
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197000200A
Other languages
English (en)
Korean (ko)
Other versions
KR20190031230A (ko
Inventor
필립 하바싸르
쟈끄 말레
체 세르게라
Original Assignee
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)
이씨엠 (엥스띠뛰 뒤 쎄르보 에 드 라 모엘 에삐니에르)
상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크
쏘흐본느 유니베흐시테
꼼미사리아 아 레네르지 아토미끄 에뜨 옥스 에너지스 앨터네이티브즈
아시스땅스 퍼블리끄-오삐또 드 빠리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름), 이씨엠 (엥스띠뛰 뒤 쎄르보 에 드 라 모엘 에삐니에르), 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크, 쏘흐본느 유니베흐시테, 꼼미사리아 아 레네르지 아토미끄 에뜨 옥스 에너지스 앨터네이티브즈, 아시스땅스 퍼블리끄-오삐또 드 빠리 filed Critical 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)
Publication of KR20190031230A publication Critical patent/KR20190031230A/ko
Application granted granted Critical
Publication of KR102317622B1 publication Critical patent/KR102317622B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020197000200A 2016-06-03 2017-06-02 Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도 Active KR102317622B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172964 2016-06-03
EP16172964 2016-06-03
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Publications (2)

Publication Number Publication Date
KR20190031230A KR20190031230A (ko) 2019-03-25
KR102317622B1 true KR102317622B1 (ko) 2021-10-26

Family

ID=56148119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000200A Active KR102317622B1 (ko) 2016-06-03 2017-06-02 Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도

Country Status (11)

Country Link
US (2) US20190185832A1 (enExample)
JP (2) JP7436145B2 (enExample)
KR (1) KR102317622B1 (enExample)
CN (2) CN109906271A (enExample)
AU (1) AU2017275769B2 (enExample)
BR (1) BR112018074930A2 (enExample)
CA (1) CA3025591A1 (enExample)
IL (1) IL263291B2 (enExample)
RU (1) RU2771383C2 (enExample)
SG (1) SG11201810772XA (enExample)
WO (1) WO2017207797A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823995A4 (en) * 2018-08-01 2022-05-04 The Regents of the University of Colorado, a body corporate PROGRAMMABLE THERAPEUTIC FUSOGENE SECRETED GECTOSOME DESIGNER VESICLES FOR MACROMOLECULE RELEASE AND GENOME MODIFICATION
CN115820654A (zh) * 2019-08-30 2023-03-21 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
CN119894540A (zh) * 2022-07-05 2025-04-25 营养治疗基因公司 人类t或nk细胞中转基因的受控表达用于细胞免疫疗法
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322184A1 (en) * 2011-11-08 2014-10-30 Institut National De La Recherche Agronomique (Inra) Inducible expression cassette, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102479178B1 (ko) * 2012-12-06 2022-12-19 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
WO2015089462A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322184A1 (en) * 2011-11-08 2014-10-30 Institut National De La Recherche Agronomique (Inra) Inducible expression cassette, and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nat Biotechnol.,33(4):390-394(2015.4.)*
Nat Chem Biol.,11(3):198-200(2015.3.)
Sci Signal.,8(374):doi: 10.1126/scisignal.aaa0549(2015.4.28.)

Also Published As

Publication number Publication date
CN109906271A (zh) 2019-06-18
KR20190031230A (ko) 2019-03-25
RU2771383C2 (ru) 2022-05-04
US20230313161A1 (en) 2023-10-05
CA3025591A1 (en) 2017-12-07
WO2017207797A1 (en) 2017-12-07
AU2017275769A1 (en) 2018-12-20
SG11201810772XA (en) 2018-12-28
IL263291B2 (en) 2023-07-01
AU2017275769B2 (en) 2023-04-13
RU2018142174A3 (enExample) 2020-09-30
JP7436145B2 (ja) 2024-02-21
US20190185832A1 (en) 2019-06-20
IL263291A (en) 2018-12-31
CN116064534A (zh) 2023-05-05
JP2022133441A (ja) 2022-09-13
BR112018074930A2 (pt) 2019-03-12
RU2018142174A (ru) 2020-07-10
IL263291B1 (en) 2023-03-01
JP2019517262A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
KR102317622B1 (ko) Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도
AU2016214301B2 (en) Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
CN110856724B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
JP2023036921A (ja) 蝸牛および前庭細胞に核酸を送達するための物質および方法
AU2017248259A1 (en) Chimeric antigen receptor T cell compositions
CN108289933B (zh) 作为认知和行为障碍药物的哺乳动物Klotho的分泌型剪接变体
KR20010024296A (ko) 벡터 구조체와 세포 ｄｎａ의 비상동 재조합법에 의한내생 유전자 발현
CN107746845A (zh) 特异性靶向LAG‑3基因的sgRNA和特异性敲除LAG‑3基因的方法
KR101961667B1 (ko) 돼지유행성설사병 바이러스에 내성을 가지는 형질전환 복제돼지 및 이의 제조방법
JP7725514B2 (ja) 結節性硬化症の遺伝子治療
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
AU2020455080B2 (en) Vaginal gel preparation and preparation method therefor
KR20210005184A (ko) 유전자 치료 방법
US20240018542A1 (en) Co-packaging to mitigate intermolecular recombination
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
KR20210102247A (ko) Crispr 수퍼-리프레서에 의한 생체내 합성 면역조절
JP2022541788A (ja) Ｈｉｖ感染症を治療するための長寿命ｔ細胞
CN109082442A (zh) 一种可解除免疫抑制并增强肿瘤靶向性杀伤的间充质干细胞的制备方法
CN113667017A (zh) 一种可提高CRISPR/Cas9系统同源重组效率的方法和应用
CN115247181A (zh) 一种用于制备脱发模型猪的核移植供体细胞的试剂盒及其制备方法
CN115704023A (zh) 靶向USH2A基因pre-mRNA的gRNA、递送系统和CRISPR-Cas系统
CN108949691B (zh) 一种制备可实时检测间充质干细胞衰老的细胞模型的方法
RU2810116C1 (ru) Вагинальный гель и метод его изготовления
CN112272565A (zh) 使用慢病毒基因构建体的递送的体内基因疗法
CN109628487A (zh) 一种利用转基因猪唾液腺制备人神经生长因子的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200409

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210318

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210923

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211020

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee